- Home
- Publications
- Publication Search
- Publication Details
Title
Platinum Resistance in Ovarian Cancer: Role of DNA Repair
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 1, Pages 119
Publisher
MDPI AG
Online
2019-01-22
DOI
10.3390/cancers11010119
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
- (2018) C Cruz et al. ANNALS OF ONCOLOGY
- Latest clinical evidence and further development of PARP inhibitors in ovarian cancer
- (2018) M R Mirza et al. ANNALS OF ONCOLOGY
- A Small-Molecule Inhibitor of Human DNA Polymerase η Potentiates the Effects of Cisplatin in Tumor Cells
- (2018) Maroof K. Zafar et al. BIOCHEMISTRY
- A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity
- (2018) Norman Sachs et al. CELL
- A novel antibody-based approach to detect the functional ERCC1-202 isoform
- (2018) Mei-Shiue Kuo et al. DNA REPAIR
- Homologous recombination and the repair of DNA double-strand breaks
- (2018) William Douglass Wright et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- How cells ensure correct repair of DNA double-strand breaks
- (2018) Joonyoung Her et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Prognostic values of excision repair cross-complementing genes mRNA expression in ovarian cancer patients
- (2018) Menghuang Zhao et al. LIFE SCIENCES
- Patient-derived tumor organoids for prediction of cancer treatment response
- (2018) Peter W. Nagle et al. SEMINARS IN CANCER BIOLOGY
- Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts
- (2018) Federica Guffanti et al. Oncotarget
- Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin
- (2018) Dominik Bieg et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- Replication Protein A Availability During DNA Replication Stress Is a Major Determinant of Cisplatin Resistance in Ovarian Cancer Cells
- (2018) François Bélanger et al. CANCER RESEARCH
- Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids
- (2018) Krijn K. Dijkstra et al. CELL
- CDK12: an emerging therapeutic target for cancer
- (2018) Goldie Y L Lui et al. JOURNAL OF CLINICAL PATHOLOGY
- Prediction of DNA Repair Inhibitor Response in Short Term Patient-Derived Ovarian Cancer Organoids
- (2018) Sarah J. Hill et al. Cancer Discovery
- Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies
- (2018) Sandro Nuciforo et al. Cell Reports
- High-throughput screening in colorectal cancer tissue-originated spheroids
- (2018) Jumpei Kondo et al. CANCER SCIENCE
- State-of-the-art strategies for targeting the DNA damage response in cancer
- (2018) Patrick G. Pilié et al. Nature Reviews Clinical Oncology
- Patient-derived organoids: New co-clinical model to predict treatment response in cancer?
- (2018) Enrique A. Castellón ORAL DISEASES
- PARP inhibitors in ovarian cancer
- (2018) Elisena Franzese et al. CANCER TREATMENT REVIEWS
- Association between polymorphisms in CTR1, CTR2, ATP7A, and ATP7B and platinum resistance in epithelial ovarian cancer
- (2017) Tailin Li et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- PARP inhibitors for targeted treatment in ovarian cancer
- (2017) Don S Dizon LANCET
- Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts
- (2017) Francesca Ricci et al. Molecular Cancer
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- High grade serous ovarian carcinomas originate in the fallopian tube
- (2017) S. Intidhar Labidi-Galy et al. Nature Communications
- Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
- (2017) Olga Kondrashova et al. Cancer Discovery
- Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies
- (2017) Eun Jin Heo et al. Cancer Research and Treatment
- The Dualistic Model of Ovarian Carcinogenesis
- (2016) Robert J. Kurman et al. AMERICAN JOURNAL OF PATHOLOGY
- PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
- (2016) G E Konecny et al. BRITISH JOURNAL OF CANCER
- Role and therapeutic potential of CDK12 in human cancers
- (2016) Rosaria Chilà et al. CANCER TREATMENT REVIEWS
- Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics
- (2016) Joyce F. Liu et al. CLINICAL CANCER RESEARCH
- In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma
- (2016) Mariam M. AlHilli et al. GYNECOLOGIC ONCOLOGY
- Dual role of LRRC8A-containing transporters on cisplatin resistance in human ovarian cancer cells
- (2016) Belinda Halling Sørensen et al. JOURNAL OF INORGANIC BIOCHEMISTRY
- Replication fork stability confers chemoresistance in BRCA-deficient cells
- (2016) Arnab Ray Chaudhuri et al. NATURE
- Cisplatin resistance and opportunities for precision medicine
- (2016) Lauren Amable PHARMACOLOGICAL RESEARCH
- Repair Pathway Choices and Consequences at the Double-Strand Break
- (2016) Raphael Ceccaldi et al. TRENDS IN CELL BIOLOGY
- The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancer
- (2016) Yan Dai et al. Oncotarget
- Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy
- (2016) Francesca Ricci et al. Oncotarget
- Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening
- (2016) Carla S Verissimo et al. eLife
- A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance
- (2015) R. Ceccaldi et al. CANCER RESEARCH
- Inhibition of the ERCC1–XPF structure-specific endonuclease to overcome cancer chemoresistance
- (2015) Ewan M. McNeil et al. DNA REPAIR
- Nucleotide excision repair in humans
- (2015) Graciela Spivak DNA REPAIR
- Crosstalk between translesion synthesis, Fanconi anemia network, and homologous recombination repair pathways in interstrand DNA crosslink repair and development of chemoresistance
- (2015) Brittany Haynes et al. MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH
- Exploiting replicative stress to treat cancer
- (2015) Matthias Dobbelstein et al. NATURE REVIEWS DRUG DISCOVERY
- Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells
- (2015) Amit Kumar Srivastava et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
- (2015) P. A. Konstantinopoulos et al. Cancer Discovery
- Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells
- (2015) Elisa Caiola et al. Oncotarget
- Predicting the outcome of platinum-based chemotherapies in epithelial ovarian cancer using the 8092C/A polymorphism ofERCC1: a meta-analysis
- (2014) Li Yan et al. BIOMARKERS
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Nucleotide excision repair: Why is it not used to predict response to platinum-based chemotherapy?
- (2014) Nikola A. Bowden CANCER LETTERS
- Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations
- (2014) F. Ricci et al. CANCER RESEARCH
- ERCC1-Positive Circulating Tumor Cells in the Blood of Ovarian Cancer Patients as a Predictive Biomarker for Platinum Resistance
- (2014) J. D. Kuhlmann et al. CLINICAL CHEMISTRY
- An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer
- (2014) Monjri M. Shah et al. GYNECOLOGIC ONCOLOGY
- Understanding nucleotide excision repair and its roles in cancer and ageing
- (2014) Jurgen A. Marteijn et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Genetic markers for prediction of treatment outcomes in ovarian cancer
- (2014) E Caiola et al. PHARMACOGENOMICS JOURNAL
- Systems biology of cisplatin resistance: past, present and future
- (2014) L Galluzzi et al. Cell Death & Disease
- Effect of hOGG1 Over-Expression on Cisplatin Resistance in Esophageal Squamous Carcinoma Cells
- (2013) Daqing Gao et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome
- (2013) K. L. White et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform
- (2013) Luc Friboulet et al. CELL CYCLE
- ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer
- (2013) Luc Friboulet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ctr2 regulates biogenesis of a cleaved form of mammalian Ctr1 metal transporter lacking the copper- and cisplatin-binding ecto-domain
- (2013) H. Ohrvik et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
- (2013) N. Johnson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- In Vivo Bypass of 8-oxodG
- (2013) Gina P. Rodriguez et al. PLoS Genetics
- Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: A gynecologic oncology group study
- (2012) Jennifer M. Rubatt et al. GYNECOLOGIC ONCOLOGY
- The DNA damage response and cancer therapy
- (2012) Christopher J. Lord et al. NATURE
- Association between polymorphisms ofERCC1and survival in epithelial ovarian cancer patients with chemotherapy
- (2012) Li Yan et al. PHARMACOGENOMICS
- Double-Strand Break Repair-Independent Role for BRCA2 in Blocking Stalled Replication Fork Degradation by MRE11
- (2011) Katharina Schlacher et al. CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Unleashing Chk1 in cancer therapy
- (2011) Laura Carrassa et al. CELL CYCLE
- Expression of DNA repair genes in ovarian cancer samples: Biological and clinical considerations
- (2011) M. Ganzinelli et al. EUROPEAN JOURNAL OF CANCER
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer
- (2011) E Caiola et al. PHARMACOGENOMICS JOURNAL
- Enhancing Tumor-Specific Uptake of the Anticancer Drug Cisplatin with a Copper Chelator
- (2010) Seiko Ishida et al. CANCER CELL
- Secondary mutations of BRCA1/2 and drug resistance
- (2010) Kiranjit K. Dhillon et al. CANCER SCIENCE
- Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
- (2010) A. Mukhopadhyay et al. CLINICAL CANCER RESEARCH
- Common mechanisms of PIKK regulation
- (2009) Courtney A. Lovejoy et al. DNA REPAIR
- Emerging common themes in regulation of PIKKs and PI3Ks
- (2009) Harri Lempiäinen et al. EMBO JOURNAL
- Impaired DNA damage response — An Achilles' heel sensitizing cancer to chemotherapy and radiotherapy
- (2009) Zbigniew Darzynkiewicz et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Role of homologous recombination in trabectedin-induced DNA damage
- (2008) M. Tavecchio et al. EUROPEAN JOURNAL OF CANCER
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
- (2008) Wataru Sakai et al. NATURE
- Resistance to therapy caused by intragenic deletion in BRCA2
- (2008) Stacey L. Edwards et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started